Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Statins reduce the incidence of cardiovascular events in persons with type 2 diabetes mellitus. However, the benefit of statins in such patients receiving hemodialysis, who are at high risk for cardiovascular disease and death, has not been examined. METHODS: We conducted a multicenter, randomized, double-blind, prospective study of 1255 subjects with type 2 diabetes mellitus receiving maintenance hemodialysis who were randomly assigned to receive 20 mg of atorvastatin per day or matching placebo. The primary end point was a composite of death from cardiac causes, nonfatal myocardial infarction, and stroke. Secondary end points included death from all causes and all cardiac and cerebrovascular events combined. RESULTS: After four weeks of treatment, the median level of low-density lipoprotein cholesterol was reduced by 42 percent among patients receiving atorvastatin, and among those receiving placebo it was reduced by 1.3 percent. During a median follow-up period of four years, 469 patients (37 percent) reached the primary end point, of whom 226 were assigned to atorvastatin and 243 to placebo (relative risk, 0.92; 95 percent confidence interval, 0.77 to 1.10; P=0.37). Atorvastatin had no significant effect on the individual components of the primary end point, except that the relative risk of fatal stroke among those receiving the drug was 2.03 (95 percent confidence interval, 1.05 to 3.93; P=0.04). Atorvastatin reduced the rate of all cardiac events combined (relative risk, 0.82; 95 percent confidence interval, 0.68 to 0.99; P=0.03, nominally significant) but not all cerebrovascular events combined (relative risk, 1.12; 95 percent confidence interval, 0.81 to 1.55; P=0.49) or total mortality (relative risk, 0.93; 95 percent confidence interval, 0.79 to 1.08; P=0.33). CONCLUSIONS: Atorvastatin had no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infarction, and stroke in patients with diabetes receiving hemodialysis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Intensive glucose control (A1C levels <7% in T2D and <7.5% in T1D) in several clinical trials was found to reduce the risk of incident albuminuria (A2) and DKD onset.70,78,90,406–410”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [407]
In the citing paper
“Finally, in the UKPDS, wherein intensive treatment led to a mean end point A1C of 7.0%, hypoglycemia occurred in 1.8% of insulin-treated persons per year in the intensive group vs 0.7% of conventionally treated persons per year.407”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [407]
In the citing paper
“CKD is strongly associated with dyslipidemia, and CVD remains the leading cause of mortality among patients with CKD.25,26,28”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
In the citing paper
“CKD is strongly associated with dyslipidemia, and CVD remains the leading cause of mortality among patients with CKD.25,26,28”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
In the citing paper
“However, because of the gaps in data and negative study results, uncertainty exists over the benefits of applying proven CVD therapy in the general population to the CKD population, especially in patients with advanced kidney disease.”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Clinical epidemiology of cardiovascular disease in chronic renal disease
Foley, R., Parfrey, P., & Sarnak, M. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v32.pm9820470 · Cited by 3,958
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Doqi, K. (2002) · American Journal of Kidney Diseases · Cited by 1,285
The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia
Himmelfarb, J., Stenvinkel, P., Ikizler, T. A., & Hakim, R. M. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00600.x · Cited by 1,179
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- Takayama F, 1998, Cell Mol Biol, 44, 1101
Cited by
Items 601–700 of 1,004
Coronary Microvascular Function in Early Chronic Kidney Disease
Charytan, D. M., Shelbert, H. R., & Carli, M. F. D. (2010) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.110.957761 · Cited by 49
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I. M., Backer, G. D., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0157 · Cited by 61
Judge, C., Ruttledge, S., Costello, M., Murphy, R., Loughlin, E., Alvarez-Iglesias, A., Ferguson, J., Gorey, S., Nolan, A., Canavan, M., et al. (2019) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2019.02.018 · Cited by 50
Yamashita, S., Arai, H., Yokote, K., Araki, E., Matsushita, M., Nojima, T., Suganami, H., & Ishibashi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225537 · Cited by 48
Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation
Barbagallo, C. M., Cefalu, A. B., Giammanco, A., Noto, D., Caldarella, R., Ciaccio, M., Averna, M. R., & Nardi, E. (2021) · Life · doi:10.3390/life11040315 · Cited by 59
Holmberg, B., & Stegmayr, B. G. (2009) · Hemodialysis International · doi:10.1111/j.1542-4758.2009.00335.x · Cited by 49
Statin Treatment and Diabetes Affect Myeloperoxidase Activity in Maintenance Hemodialysis Patients
Stenvinkel, P., Accent]guez-Ayala, E. R. A., Massy, Z. A., Qureshi, A. R., Barany, P. F., Diaeresis]m, B. F., Heimbürger, O., Lindholm, B., & Alvestrand, A. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01281005 · Cited by 49
Athyros, V. G., Katsiki, N., Karagiannis, A. I., & Mikhailidis, D. P. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1053464 · Cited by 52
Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review
Ferri, N., Ruscica, M., Fazio, S., & Corsini, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040943 · Cited by 51
Vitamin D Receptor Activation and Left Ventricular Hypertrophy in Advanced Kidney Disease
Thadhani, R., Appelbaum, E. A., Chang, Y., Pritchett, Y., Bhan, I., Agarwal, R., Zoccali, C., Wanner, C., Lloyd‐Jones, D. M., Cannata-Andía, J. B., et al. (2011) · American Journal of Nephrology · doi:10.1159/000323551 · Cited by 48
Self-citationBargnoux, A., Dupuy, A., Garrigue, V., Jaussent, I., Gahide, G., Badiou, S., Szwarc, I., Deleuze, S., Vernhet, H., Cristol, J., et al. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02814.x · Cited by 48
The Role of Statins in Chronic Kidney Disease
Kalaitzidis, R., & Elisaf, M. (2011) · American Journal of Nephrology · doi:10.1159/000330355 · Cited by 50
Dialysis-Induced Myocardial Stunning: The Other Side of the Cardiorenal Syndrome
Breidthardt, T., & McIntyre, C. W. (2011) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm0585 · Cited by 53
Valvular Calcification in Chronic Kidney Disease
Brandenburg, V. M., Schuh, A., & Kramann, R. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.10.004 · Cited by 48
Perelló, J., Ferrer, M. D., Pérez, M. D. M., Kaesler, N., Güney, A., Brandenburg, V. M., Behets, G. J. S., D’Haese, P. C., Garg, R., Isern, B., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15163 · Cited by 49
van Oosten, M. J. M., Logtenberg, S. J. J., Hemmelder, M. H., Leegte, M. J. H., Bilo, H. J. G., Jager, K. J., & Stel, V. S. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab120 · Cited by 50
Therapeutic Strategies for Heart Failure in Cardiorenal Syndromes
House, A. A., Haapio, M., Lassus, J. P. E., Bellomo, R., & Ronco, C. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.04.012 · Cited by 56
Kidney Transplantation in the Context of Renal Replacement Therapy
Pesavento, T. E. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05500809 · Cited by 48
Kalantar‐Zadeh, K. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02750707 · Cited by 57
Herzog, C. A. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp733 · Cited by 48
[Consensus document on treatment of type 2 diabetes in patients with chronic kidney disease].
Gómez‐Huelgas, R., Martínez‐Castelao, A., Artola, S., Górriz, J. L., & Menéndez, E. (2014) · PubMed · Cited by 53
Cardiovascular disease in chronic kidney disease: risk factors, pathogenesis, and prevention.
Ardhanari, S., Alpert, M., & Aggarwal, K. B. (2014) · PubMed · Cited by 57
Omega-3 Fatty Acid Supplementation in Advanced Kidney Disease
Friedman, A. N. (2010) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2010.00748.x · Cited by 49
Goldfarb‐Rumyantzev, A. S., Habib, A. N., Baird, B. C., Barenbaum, L. L., & Cheung, A. K. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.07.023 · Cited by 47
New Insights Into Lipid Metabolism in Chronic Kidney Disease
Kaysen, G. A. (2011) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2010.10.017 · Cited by 47
Banerjee, D., Mayoral, A. R., Chitalia, N., & Kaski, J. C. (2011) · Clinical Cardiology · doi:10.1002/clc.20901 · Cited by 49
Meta-Analysis of Effect of Statin Treatment on Risk of Sudden Death
Levantesi, G., Scarano, M., Marfisi, R., Borrelli, G., Rutjes, A. W., Silletta, M. G., Tognoni, G., & Marchioli, R. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.07.015 · Cited by 50
Zawada, A. M., Rogacev, K. S., Hummel, B., Grün, O. S., Friedrich, A., Rotter, B., Winter, P., Geisel, J., Fliser, D., & Heine, G. H. (2012) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.112.963207 · Cited by 52
McGraw, N., Krul, E. S., Grunz‐Borgmann, E. A., & Parrish, A. R. (2016) · World Journal of Nephrology · doi:10.5527/wjn.v5.i3.233 · Cited by 52
Verbeke, F., Siwy, J., Biesen, W. V., Mischak, H., Pletinck, A., Schepers, E., Neirynck, N., Magalhães, P., Pejchinοvski, M., Pontillo, C., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz242 · Cited by 47
The effects of statins on high-density lipoproteins
Schaefer, E. J., & Asztalos, B. F. (2006) · Current Atherosclerosis Reports · doi:10.1007/s11883-006-0063-3 · Cited by 48
Postorino, M., Marino, C., Tripepi, G. L., & Zoccali, C. (2010) · Kidney International · doi:10.1038/ki.2010.493 · Cited by 47
The current status of interventions aiming at reducing sudden cardiac death in dialysis patients
de Bie, M. K., van Dam, B., Gaasbeek, A., van Buren, M., van Erven, L., Bax, J. J., Schalij, M. J., Rabelink, T. J., & Jukema, J. W. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp185 · Cited by 47
Improving Physical Functioning: Time to Be a Part of Routine Care
Painter, P., & Johansen, K. L. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.05.004 · Cited by 47
The association of statin therapy and cancer: a meta-analysis
Chen, Z., Wu, P., Wang, J., Chen, P., Fang, Z., & Luo, F. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01955-4 · Cited by 48
Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 97
Dialysate and Serum Potassium in Hemodialysis
Hung, A. M., & Hakim, R. M. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.02.322 · Cited by 51
Accuracy and Limitations of the Diagnosis of Malnutrition in Dialysis Patients
Kovesdy, C. P., & Kalantar‐Zadeh, K. (2012) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2012.01097.x · Cited by 46
de Bie, M. K., Koopman, M. G., Gaasbeek, A., Dekker, F. W., Maan, A. C., Swenne, C. A., Scherptong, R. W. C., van Dessel, P. F. H. M., Wilde, A. A. M., Schalij, M. J., et al. (2012) · EP Europace · doi:10.1093/europace/eus306 · Cited by 46
Lipid-lowering therapy: who can benefit
Lewis, S. J. (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s23113 · Cited by 52
Lardizabal, J. A., & DEEDWANIA, P. C. (2011) · Cardiology Clinics · doi:10.1016/j.ccl.2010.10.002 · Cited by 48
Roberts, M. A., Pilmore, H., Ierino, F. L., Badve, S. V., Cass, A., Garg, A. X., Isbel, N. M., Krum, H., Pascoe, E. M., Perkovic, V., et al. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.10.029 · Cited by 46
Yeang, C., Cotter, B. R., & Tsimikas, S. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6634-1 · Cited by 47
Metabolic risk profile in kidney transplant candidates and recipients
Piotti, G., Gandolfini, I., Palmisano, A., & Maggiore, U. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy151 · Cited by 48
Kelly, D., & Rothwell, P. M. (2019) · Kidney International · doi:10.1016/j.kint.2019.09.024 · Cited by 49
Edmonston, D., Isakova, T., Dember, L., Brunelli, S., Young, A., Brosch, R., Beddhu, S., Chakraborty, H., & Wolf, M. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.10.008 · Cited by 37
Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients
Davis, J. W., & Weller, S. C. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043714 · Cited by 48
Renal Function and Coronary Microvascular Dysfunction in Women with Symptoms/Signs of Ischemia
Mohandas, R., Segal, M. S., Huo, T., Handberg, E. M., Petersen, J. W., Johnson, B. D., Sopko, G. S., Merz, C. N. B., & Pepine, C. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125374 · Cited by 46
Alterations of Lipid Metabolism in Chronic Nephropathies: Mechanisms, Diagnosis and Treatment
Lacquaniti, A., Bolignano, D., Donato, V., Bono, C., Fazio, M. R., & Buemi, M. (2010) · Kidney & Blood Pressure Research · doi:10.1159/000302712 · Cited by 54
Ma, Y., Wen, X., Peng, J., Lu, Y., Guo, Z., & Lu, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051548 · Cited by 46
Karthikeyan, V., & Ananthasubramaniam, K. (2009) · Current Cardiology Reviews · doi:10.2174/157340309788970342 · Cited by 50
Nephroprotective and clinical potential of statins in dialyzed patients
Rysz, J., Aronow, W. S., Stolarek, R. S., Hannam, S., Mikhailidis, D. P., & Banach, M. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902882130 · Cited by 45
Lamprea-Montealegre, J. A., McClelland, R. L., Astor, B. C., Matsushita, K., Shlipak, M. G., de Boer, I. H., & Szklo, M. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300624 · Cited by 49
Vanholder, R. C., Laecke, S. V., Glorieux, G., Verbeke, F., Castillo-Rodríguez, E., & Ortíz, A. (2018) · Toxins · doi:10.3390/toxins10060237 · Cited by 48
The effect of chronic kidney disease on lipid metabolism
Dinçer, N., Dağel, T., Afşar, B., Covic, A. C., Ortíz, A., & Kanbay, M. (2018) · International Urology and Nephrology · doi:10.1007/s11255-018-2047-y · Cited by 52
Statins and All‐Cause Mortality in Patients Undergoing Hemodialysis
Jung, J., Bae, G. H., Kang, M., Kim, S. W., & Lee, D. H. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014840 · Cited by 47
The randomized clinical trial: An unbeatable standard in clinical research?
Stel, V. S., Jager, K. J., Zoccali, C., Wanner, C., & Dekker, F. W. (2007) · Kidney International · doi:10.1038/sj.ki.5002354 · Cited by 45
Self-citationEffects of ezetimibe on atherosclerosis in preclinical models
Davis, H. R., Lowe, R. S., & Neff, D. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.02.010 · Cited by 48
Kalantar‐Zadeh, K. (2007) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2007.00360.x · Cited by 47
Kalantar-Zadeh, K. (2012) · Diabetes Care · doi:10.2337/dc12-0483 · Cited by 44
Cardiovascular Problems on Hemodialysis: Current Deficits and Potential Improvement
Ritz, E., & Bommer, J. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01960309 · Cited by 52
Self-citationRogacev, K. S., Heine, G. H., Silbernagel, G., Kleber, M. E., Seiler, S., Emrich, I. E., Lennartz, S., Werner, C. M., Zawada, A. M., Fliser, D., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146920 · Cited by 44
Self-citationCan We Prevent Sudden Cardiac Death in Dialysis Patients?
Herzog, C. A. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01130307 · Cited by 44
Cerebrovascular Events in Renal Transplant Recipients
Abedini, S., Holme, I., Fellström, B., Jardine, A. G., Cole, E., Maes, B., & Holdaas, H. (2009) · Transplantation · doi:10.1097/tp.0b013e31818bfce8 · Cited by 44
Akbari, A., Knoll, G. A., Ferguson, D., McCormick, B. B., Davis, A., & Biyani, M. (2009) · Peritoneal Dialysis International · doi:10.1177/089686080902900514 · Cited by 46
Use of Antimicrobial Catheter Lock Solutions to Prevent Catheter-Related Bacteremia
Bleyer, A. J. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00290107 · Cited by 54
Global cardiovascular protection in chronic kidney disease
Ruiz‐Hurtado, G., Sarafidis, P. A., Fernández‐Alfonso, M. S., Waeber, B., & Ruilope, L. M. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.48 · Cited by 45
The clinical epidemiology of cardiovascular disease in chronic kidney disease
Shik, J., & Parfrey, P. S. (2005) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000170752.64150.88 · Cited by 44
Aeschbacher‐Germann, M., Kaiser, N., Speierer, A., Blum, M. R., Bauer, D. C., Giovane, C. D., Aujesky, D., Gencer, B., Rodondi, N., & Moutzouri, E. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.026551 · Cited by 46
Yamashita, S., Rizzo, M., Su, T., & Masuda, D. (2023) · Metabolites · doi:10.3390/metabo13050626 · Cited by 44
Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled
Elewa, U., Sánchez-Niño, M. D., Martín-Cleary, C., Fernández‐Fernández, B., Egido, J., & Ortíz, A. (2012) · International Urology and Nephrology · doi:10.1007/s11255-012-0271-4 · Cited by 50
Cardiovascular Death in Dialysis Patients: Lessons We Can Learn from AURORA
Sniderman, A. D., Solhpour, A., Alam, A., Williams, K., & Sloand, J. A. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06300909 · Cited by 43
Atheroma Progression in Chronic Kidney Disease
Rigatto, C., Levin, A., House, A. A., Barrett, B. J., Carlisle, E., & Fine, A. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01840408 · Cited by 43
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Storey, B. C., Staplin, N., Haynes, R., Reith, C. A., Emberson, J., Herrington, W. G., Wheeler, D. C., Walker, R. J., Fellström, B., Wanner, C., et al. (2017) · Kidney International · doi:10.1016/j.kint.2017.09.011 · Cited by 47
Self-citationThe emerging concept of “individualized cholesterol-lowering therapy”: A change in paradigm
Lütjohann, D., Stellaard, F., Mulder, M. T., Sijbrands, E. J. G., & Weingärtner, O. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.004 · Cited by 44
Pleiotropic effects of the non-calcium phosphate binder sevelamer
Nikolov, I. G., Joki, N., Maizel, J., Lacour, B., Drüeke, T. B., & Massy, Z. A. (2006) · Kidney International · doi:10.1038/sj.ki.5001994 · Cited by 43
Kessler, M., Zannad, F. M., Lehert, P., Grünfeld, J., Thuilliez, C., Leizorovicz, A., Lechat, P. P., & for the FOSIDIAL Investigators (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm417 · Cited by 43
Dyslipidemia in chronic kidney disease: Causes and consequences
Kaysen, G. A. (2006) · Kidney International · doi:10.1038/sj.ki.5001979 · Cited by 43
Estimation et caractérisation de l’insuffisance rénale chronique en France
Bongard, V., Dallongeville, J., Arveiler, D., Ruidavets, J., Cottel, D., Wagner, A., & Ferrières, J. (2012) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2012.03.003 · Cited by 43
Kanbay, M., Güldan, M., Özbek, L., Çöpür, S., Covic, A. S., & Covic, A. C. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.07.014 · Cited by 42
Bangalore, S., Fayyad, R. S., Hovingh, G. K., Laskey, R. E., Vogt, L., DeMicco, D. A., & Waters, D. D. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.03.046 · Cited by 43
Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease
Sharma, S., Farrington, K., Kozarski, R., Christopoulos, C., Niespialowska-Steuden, M., Moffat, D., & Gorog, D. A. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs300 · Cited by 42
Streja, E., Gosmanova, E. O., Molnar, M. Z., Soohoo, M., Moradi, H., Potukuchi, P. K., Kalantar‐Zadeh, K., & Kovesdy, C. P. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.2311 · Cited by 43
Sasaki, K., Shoji, T., Kabata, D., Shintani, A., Okute, Y., Tsuchikura, S., Shimomura, N., Tsujimoto, Y., Nakatani, S., Mori, K., et al. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.56069 · Cited by 42
Freedman, B. I. (2012) · Diabetes Care · doi:10.2337/dc12-0027 · Cited by 42
Cardioprotective medication use in hemodialysis patients
Miller, L., Hopman, W. M., Garland, J. S., Yeates, K., & Pilkey, R. M. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70291-4 · Cited by 43
Chapter 5: Referral to specialists and models of care
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.68 · Cited by 47
Calcimimetics in chronic kidney disease: evidence, opportunities and challenges
Evenepoel, P. (2008) · Kidney International · doi:10.1038/ki.2008.166 · Cited by 44
Mehrotra, R., Kalantar‐Zadeh, K., & Adler, S. G. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04210511 · Cited by 42
Loss of Y Chromosome and Cardiovascular Events in Chronic Kidney Disease
Weyrich, M., Cremer, S., Gerster, M., Sarakpi, T., Rasper, T., Zewinger, S., Patyna, S., Leistner, D. M., Heine, G. H., Wanner, C., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069139 · Cited by 41
Self-citationHibbert, B. M., Ma, X., Pourdjabbar, A., Simard, T., Rayner, K. J., Sun, J., Chen, Y., Filion, L. G., & O’Brien, E. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016413 · Cited by 44
Restoration of Renal Function Does Not Correct Impairment of Uremic HDL Properties
Kopecky, C., Haidinger, M., Birner‐Gruenberger, R., Darnhofer, B., Kaltenecker, C. C., Marsche, G., Holzer, M., Weichhart, T., Antlanger, M., Kovarik, J. J., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013111219 · Cited by 41
Kollerits, B., Drechsler, C., Krane, V., Lamina, C., März, W., Dieplinger, H., Ritz, E., Wanner, C., & Kronenberg, F. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv428 · Cited by 42
Self-citationGraham-Brown, M. P. M., March, D. S., Churchward, D. R., Young, H. M. L., Dungey, M. R., Lloyd, S. M., Brunskill, N. J., Smith, A. C., McCann, G. P., & Burton, J. O. (2016) · BMC Nephrology · doi:10.1186/s12882-016-0294-7 · Cited by 45
Murali, K., Mullan, J., Chen, J. H. C., Roodenrys, S. J., & Lonergan, M. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0449-1 · Cited by 43
Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function
Stanifer, J. W., Charytan, D. M., White, J. A., Lokhnygina, Y. V., Cannon, C. P., Roe, M. T., & Blazing, M. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016090957 · Cited by 41
Dialysis Prescription and Sudden Death
Rhee, C. M., Chou, J. A., & Kalantar‐Zadeh, K. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.08.003 · Cited by 41
Trends in Statin Use Among US Adults With Chronic Kidney Disease, 1999–2014
Mefford, M. T., Rosenson, R. S., Deng, L., Tanner, R. M., Bittner, V., Safford, M. M., Coll, B., Mues, K. E., Monda, K. L., & Muntner, P. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.010640 · Cited by 42
Fried, T. R., & Mecca, M. C. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15798 · Cited by 41
Marsche, G., Heine, G. H., Stadler, J. T., & Holzer, M. (2020) · Biomolecules · doi:10.3390/biom10091348 · Cited by 42
Metadata
- Authors
- Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E.
- Affiliations
- University of Würzburg (DE)
- Medical University of Graz (AT)
- University Medical Center Freiburg (DE)
- München Klinik Schwabing (DE)
- Pfizer (Germany) (DE)
- Heidelberg University (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-07-21
- Volume
- 353
- Issue
- 3
- Pages
- 238-248
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2110601215
- Cited by
- 2,614
- References
- 30
- Citations by year
- 2026: 74 · 2025: 51 · 2024: 66 · 2023: 76 · 2022: 90 · 2021: 92 · 2020: 97 · 2019: 110 · 2018: 96 · 2017: 104 · 2016: 110 · 2015: 132 · 2014: 153 · 2013: 162 · 2012: 185
- FWCI
- 135.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- atorvastatin, type 2 diabetes, hemodialysis, statins, cardiovascular events, myocardial infarction, stroke, cardiovascular mortality, LDL cholesterol, end-stage renal disease
- MeSH terms
- Atorvastatin, Aged, Cerebrovascular Disorders, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Heart Diseases, Renal Dialysis, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Prospective Studies, Pyrroles, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.